New drug trial aims to tame dangerous liver scarring
NCT ID NCT07364448
Summary
This study is testing the safety of an experimental capsule called hydronidone in people with liver fibrosis (scarring) caused by chronic hepatitis B or fatty liver disease. About 200 participants will take the capsules three times a day for 28 days. The main goal is to see what side effects, if any, occur during treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B WITH HEPATIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jilin University First Hospital
Jilin, Changchun, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.